Article

Long-Term Clinical Outcomes After Angiographically Defined Very Late Stent Thrombosis of Drug-Eluting Stent

Division of Cardiology, Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, South Korea.
Clinical Cardiology (Impact Factor: 2.59). 09/2009; 32(9):526-9. DOI: 10.1002/clc.20648
Source: PubMed

ABSTRACT

The advent of drug-eluting stent (DES) use has raised concerns regarding later occurring stent thrombosis, especially very late stent thrombosis (VLST), and little is known about long-term clinical outcomes after VLST occurrence.
Long-term clinical outcomes after detection of VLST may be poor.
We evaluated 3572 consecutive patients who received DES implantation from May 2004 to July 2007 at 3 hospitals. The primary outcomes were a composite of major adverse cardiac events (MACE) including cardiac death, myocardial infarction (MI), target-lesion revascularization (TLR), and target-vessel revascularization (TVR) after VLST occurrence.
We identified 19 patients (0.53%) with angiographically documented stent thrombosis developing over 1 year after DES implantation. The mean time to VLST occurrence was 899 days (899 +/- 353). Discontinuation of antiplatelet drugs was noted in 4 (21%) patients and the average duration of discontinuation was 4 days. Clinical presentations of VLST were mainly MI (17 patients, 89%). Balloon angioplasty was only performed in 12 patients (63%) and stent implantation in 7 patients (37%). Mean follow-up duration from VLST occurrence was 620 days (620+/-256). During clinical follow-up after VLST occurrence, no cardiac deaths or MIs were detected. Target-vessel revascularization was done in 2 (11%) patients and TLR in 1 patient (6%). Major adverse cardiac events occurred in 3 (16%) patients during long-term clinical follow-up.
Clinical presentation of VLST after DES implantation is associated with serious adverse events, such as MI. Long-term follow-up outcomes after VLST occurrence appear unfavorable and more data from larger studies are warranted.

Full-text preview

Available from: onlinelibrary.wiley.com
  • [Show abstract] [Hide abstract]
    ABSTRACT: ACC/AHA/SCAI recommendations include dual anti-platelet therapy (aspirin and clopidogrel) for 12 months after drug-eluting stent percutaneous coronary intervention (DES PCI). Numerous case reports have emerged of "very late stent thrombosis" (VLST) (>1 year post-DES-PCI) even 1-5 years after DES-PCI manifesting with myocardial infarction and death when clopidogrel therapy was interrupted or stopped. We hypothesize that a novel regimen of alternate day clopidogrel would provide a cost-effective strategy to prevent VLST taking into account the known facts about clopidogrel pharmacodynamics, stent endothelialization and stent thrombosis. We hypothesized that the degree of anti-platelet effect required to prevent VLST decreases with time as the stent endothelializes-that is the "therapeutic threshold" required to prevent VLST decreases with time. The anti-platelet effect of clopidogrel lasts for 5-7 days. Typically, stent thrombosis on interruption of clopidogrel (with bare metal stents within first 30 days) occurs after 3-4 days signifying recovery of enough platelet function to produce stent thrombosis--recovery of platelet inhibition beyond the therapeutic threshold. Since the therapeutic threshold required to prevent VLST in DES after 1 year is much lower, this degree of platelet inhibition can be conceivably achieved with just administering clopidogrel on alternate days. EMPIRICAL DATA: We studied efficacy and safety of regimen of daily aspirin 81 mg and alternate-day clopidogrel 75 mg beyond 12 months after PCI with DES for prevention of VLST by following 347 patients for occurrence of death, myocardial infarction (MI), VLST, target vessel revascularization (TVR) and bleeding. There were no occurrence of major bleeding, VLST events or death. Long term dual anti-platelet therapy with aspirin 81 mg daily and clopidogrel 75 mg every other day beyond 12 months after PCI with DES may be a safe and efficacious cost-saving strategy to prevent VLST.
    No preview · Article · Nov 2011 · Medical Hypotheses
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: The application of coronary stents, especially drug-eluting stents (DESs), has made percutaneous coronary intervention (PCI) one of important therapeutic methods for CHD. DES has reduced the in-stent restenosis to 5%-9% and significantly improved the long-term prognosis of patients with CHD. The study aimed to investigate the long-term efficacy and safety of domestic drug-eluting stents (DESs) in patients with acute coronary syndrome (ACS). Methods: All patients with ACS who had undergone successful percutaneous coronary intervention (PCI) in the First Affiliated Hospital of Zhengzhou University from July 2009 to December 2010 were included in this study. Patients were excluded from the study if they were implanted with bare metal stents or different stents (domestic and imported DESs) simultaneously. The included patients were divided into two groups according to different stents implanted: domestic DESs and imported DESs. Results: In the 1 683 patients of this study, 1 558 (92.6%) patients were followed up successfully for an average of (29.1±5.9) months. 130 (8.3%) patients had major adverse cardiovascular events (MACEs), including cardiac death in 32 (2.1%) patients, recurrent myocardial infarction in 16 (1%), and revascularization in 94 (6%). The rates of cardiac death, recurrent myocardial infarction, revascularization, in-stent restenosis, stent thrombosis and other MACEs were not significantly different between the two groups (all P>0.05). Multivarite logistic regression revealed that diabetes mellitus (OR=1.75, 95%CI: 1.09-2.82, P=0.021), vascular numbers of PCI (OR=2.16, 95%CI: 1.22-3.83, P=0.09) and PCI with left main lesion (OR=9.47, 95%CI: 2.96-30.26, P=0.01) were independent prognostic factors of MACEs. The Kaplan-Meier method revealed that there was no significant difference in cumulative survival rates and survival rates free from clinical events between the two groups (all P>0.05). Conclusions: The incidences of clinical events and cumulative survival rates are not statistically different between domestic DESs and imported DESs. Domestic DES is effective and safe in the treatment of patients with ACS.
    Full-text · Article · Sep 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To investigate the long term efficacy and safety of domestic drug-eluting stents (DES) in patients with acute coronary syndrome (ACS) following percutaneous coronary intervention (PCI). Methods: All patients with ACS treated with successful PCI from July 2009 to December 2010 were included in this study. Patients were excluded from analysis if they were implanted with bare metal stents or different kinds of stents (domestic and imported DES) simultaneously. Clinical, laboratory, angiographic and procedural data were collected. Clinical follow-up was done through patient visits, telephone interview, and medical record review and adverse cardiac events were recorded. The patients were divided into two groups according to different stents implanted: domestic DES and imported DES. Comparisons between continuous variables were made using the Student t-test or Wilcoxon rank-sum test. Categorical data were tested using χ2 test or the Fisher exact test. Multivariate logistic regression analysis was performed to identify independent predictors of events. Cumulative survival curves were constructed using the Kaplan-Meier method and comparisons made using log-rank tests. All statistical analyses were performed using SPSS 17. 0 software, and a two-tailed P value of < 0. 05 was considered statistically significant. Results: (1) There were 1683 patients enrolled in the analysis and 1558 (92. 6%) of them were successfully followed-up. Mean follow-up time was (29. 1 ±5. 9) months. There were 130 (8. 3%) cases subjected to major adverse cardiovascular events (MACE), including 32 (2. 1%) cases with cardiac death, 16 (1%) cases with re-myocardial infarction, and 94 (6%) cases with revascularization. (2) The rates of all cause death, cardiac death, re-infarction, revascularization, in-stent restenosis, in-stent thrombosis and MACE were not significantly different between the two groups (all P > 0. 05). (3) Multivariate logistic regression revealed that diabetes mellitus (OR = 1.15, 95% CI; 1. 09-2. 82, P = 0. 021), vascular numbers of PCI (OR = 2. 16, 95% C/: 1. 22-3. 83, P = 0. 09) and PCI with left main lesion (OR = 9.47, 95% CI: 2. 96-30. 26, P = 0. 01) were independent prognostic factors of MACE; and left ventricle ejection fraction < 40% (OR = 1. 34, 95% CI: 1. 13-1. 86, P = 0. 014) was independent prognostic factors of in-stent thrombosis. (4) Kaplan-Meier survival curve revealed that there were not significant difference in cumulative rates of survival and non-clinical events rates of survival between two groups (all P > 0. 05). Conclusion: The incidences of clinical events and cumulative rates of survival were not statistical different between domestic DES and imported DES groups. Domestic DES for PCI is effective and safe in patients with ACS.
    No preview · Article · Jan 2015 · Chinese Journal of Emergency Medicine
Show more